Related Experiment Video

Updated: Jul 30, 2025

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.5K

Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a

Victor Chien-Chia Wu1,2, Chien-Hao Huang2,3, Chun-Li Wang1,2

  • 1Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan City 333423, Taiwan.

European Heart Journal. Cardiovascular Pharmacotherapy
|May 12, 2023
PubMed

Insights

Direct acting antiviral (DAA) treatment significantly reduces cardiovascular events and mortality in chronic hepatitis C virus (HCV) patients. DAA therapy showed the most significant impact in reducing venous thromboembolism (VTE) among cardiovascular outcomes.

Area of Science:

  • Hepatology
  • Cardiology
  • Infectious Diseases

Background:

  • Chronic hepatitis C virus (HCV) infection is a known risk factor for cardiovascular diseases.
  • Understanding the impact of antiviral therapies on cardiovascular outcomes in HCV patients is crucial.

Purpose of the Study:

  • To investigate the effect of direct-acting antiviral (DAA) treatment on cardiovascular events in patients with chronic HCV infection.
  • To compare cardiovascular outcomes between HCV patients who received DAA treatment and those who did not.

Main Methods:

  • Retrospective cohort study utilizing multi-institutional electronic medical records.
  • Patients with chronic HCV were divided into DAA treatment and non-DAA treatment groups.
  • Primary outcomes included acute coronary syndrome, heart failure, venous thromboembolism, stroke, cardiovascular death, MACE, and all-cause mortality, analyzed using inverse probability of treatment weighting.

Main Results:

  • DAA treatment was associated with significantly decreased rates of heart failure (HR: 0.65), venous thromboembolism (HR: 0.19), major adverse cardiovascular events (HR: 0.73), and all-cause mortality (HR: 0.50) at 3-year follow-up.
  • The study included 1984 patients in the DAA group and 413 in the non-DAA group after exclusions.
  • The reduction in venous thromboembolism (VTE) was the most pronounced cardiovascular benefit observed with DAA treatment.

Conclusions:

  • Direct-acting antiviral (DAA) treatment in chronic HCV patients leads to lower incidence of cardiovascular events and all-cause mortality compared to untreated patients.
  • DAA therapy demonstrates a significant protective effect against major adverse cardiovascular events and mortality in the HCV population.
  • The most substantial benefit of DAA treatment among cardiovascular outcomes was the significant reduction in venous thromboembolism (VTE).
Abstract

Keywords:
Cardiovascular eventsDirect acting antiviralHepatitis C virusOutcomeSustained virologic response

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

13.4K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.9K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.0K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
718
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
12